Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134256 | 0.94 | KDM4E (0.55) | KDM4ENPC1RAB9AKMT2AMEN1 | |
| SCHEMBL9142407 | 0.83 | KDM4E (0.63) | KDM4ENPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7153475 | 0.78 | KDM4E (0.50) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL17567325 | 0.78 | KDM4E (0.50) | KDM4ENPC1RAB9AMAPTAKR1B1 | |
| SCHEMBL31085210 | 0.76 | KDM4E (0.54) | KDM4ENPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4420510 | 0.76 | AKR1B1 (0.43) | KDM4ENPC1RAB9AMAPTRARA | |
| SCHEMBL30134339 | 0.76 | KDM4E (0.54) | KDM4ENPC1RAB9AKMT2AMEN1 | |
| SCHEMBL102971 | 0.75 | KDM4E (0.89) | KDM4ENPC1RAB9AKMT2AMEN1 | |
| 3,4-Methylendioxy Acetophenone SCHEMBL29405437 | 0.75 | KDM4E (0.71) | KDM4ENPC1RAB9AKMT2AMEN1 | |
| 3,4-Methylendioxy Acetophenone SCHEMBL137979 | 0.75 | KDM4E (0.71) | KDM4ENPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023011456-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BEIGENE, LTD. (KY) | 2023-02-09 | — | — | WO | disclosed |
| US-7893256-B2 | Azabicycloalkane compounds | THERAVANCE, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100197922-A1 | AZABICYCLOALKANE COMPOUNDS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | KDM4E 2009/4885NPC1 2052/4885RAB9A 981/4885 |
| US-20100197922-A1 | AZABICYCLOALKANE COMPOUNDS | ADRB1, ADRB2, ADRA2B | KDM4E 1429/4885NPC1 1982/4885RAB9A 1444/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | KDM4E 2009/4885NPC1 2052/4885RAB9A 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.